Abstract
ABSTRACTAvian influenza viruses of the H7 hemagglutinin (HA) subtype present a significant public health threat, as evidenced by the ongoing outbreak of human A(H7N9) infections in China. When evaluated by hemagglutination inhibition (HI) and microneutralization (MN) assays, H7 viruses and vaccines are found to induce lower level of neutralizing antibodies (nAb) than do their seasonal counterparts, making it difficult to develop and evaluate prepandemic vaccines. We have previously shown that purified recombinant H7 HA appear to be poorly immunogenic in that they induce low levels of HI and MN antibodies. In this study, we immunized mice with whole inactivated reverse genetics reassortant (RG) viruses expressing HA and neuraminidase (NA) from 3 different H7 viruses [A/Shanghai/2/2013(H7N9), A/Netherlands/219/2003(H7N7), and A/New York/107/2003(H7N2)] or with human A(H1N1)pdm09 (A/California/07/2009-like) or A(H3N2) (A/Perth16/2009) viruses. Mice produced equivalent titers of antibodies to all viruses as measured by enzyme-linked immunosorbent assay (ELISA). However, the antibody titers induced by H7 viruses were significantly lower when measured by HI and MN assays. Despite inducing very low levels of nAb, H7 vaccines conferred complete protection against homologous virus challenge in mice, and the serum antibodies directed against the HA head region were capable of mediating protection. The apparently low immunogenicity associated with H7 viruses and vaccines may be at least partly related to measuring antibody titers with the traditional HI and MN assays, which may not provide a true measure of protective immunity associated with H7 immunization. This study underscores the need for development of additional correlates of protection for prepandemic vaccines.IMPORTANCE H7 avian influenza viruses present a serious risk to human health. Preparedness efforts include development of prepandemic vaccines. For seasonal influenza viruses, protection is correlated with antibody titers measured by hemagglutination inhibition (HI) and virus microneutralization (MN) assays. Since H7 vaccines typically induce low titers in HI and MN assays, they have been considered to be poorly immunogenic. We show that in mice H7 whole inactivated virus vaccines (WIVs) were as immunogenic as seasonal WIVs, as they induced similar levels of overall serum antibodies. However, a larger fraction of the antibodies induced by H7 WIV was nonneutralizing in vitro. Nevertheless, the H7 WIV completely protected mice against homologous viral challenge, and antibodies directed against the HA head were the major contributor toward immune protection. Vaccines against H7 avian influenza viruses may be more effective than HI and virus neutralization assays suggest, and such vaccines may need other methods for evaluation.
Highlights
Avian influenza viruses of the H7 hemagglutinin (HA) subtype present a significant public health threat, as evidenced by the ongoing outbreak of human A(H7N9) infections in China
We used whole inactivated vaccine (WIV) preparations expressing HA and NA derived from three H7 viruses [(A/Shanghai/2/2013(H7N9) (SH/2), A/Netherlands/219/2003(H7N7) (NL/219), and A/New York/107/2003(H7N2) (NY/ 107)], one H1 virus [(A/Texas/5/2009(H1N1pdm09), antigenically identical to the prototypical H1N1pdm09 virus A/California/07/2009(H1N1pdm09) (CA/07) and referred as CA/07-like)], and one H3 virus [(A/Perth/16/2009(H3N2) (Perth/16)]
To determine if H7, H1, and H3 viruses were comparably immunogenic in the mouse model, we immunized BALB/c mice twice at 3-week intervals and measured mouse IgG antibody responses to H7 and seasonal whole inactivated virus vaccines (WIVs) immunogens by enzyme-linked immunosorbent assay (ELISA)
Summary
Avian influenza viruses of the H7 hemagglutinin (HA) subtype present a significant public health threat, as evidenced by the ongoing outbreak of human A(H7N9) infections in China. Even in virologically confirmed human cases of H7 virus infection, titers of neutralizing serum antibodies (nAb) as measured by hemagglutination inhibition (HI) and microneutralization (MN) assays have often been undetectable or low compared to titers typically induced by human seasonal viruses [6,7,8,9,10,11,12]. Vaccines against human seasonal influenza A viruses (H1N1 and H3N2 subtypes) are most often composed of reassortant viruses, expressing the appropriate HA and neuraminidase (NA), that have been inactivated using compounds such as -propiolactone (BPL) Such seasonal inactivated vaccines are capable of inducing HI titers of 40 or greater in recipients; a titer of 40 has been correlated with protection against seasonal influenza virus infection in 50% of the population cohorts [19,20,21]. Efforts have been made to explore components of H7 immunity other than neutralizing antibodies [31]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.